Last updated on June 2019

Use of Biosimilar Nivestim to Prevent Chemo-induced Neutropenia. Real Life Study


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Chemotherapy-Induced Neutropenia
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    Patients aged at least 18 years, seen by the oncologist for chemotherapy for solid
    tumour.
    Patients for whom the oncologist has decided the initiation of G-CSF biosimilar
    treatment (Nivestim®) in primary or secondary prophylaxis.
    Patients informed about the computer processing of their medical data and their right
    of access and correction.

You may not be eligible for this study if the following are true:

  • Patients with contraindication of use of Nivestim®.
    Patients with haematological malignancy including Myelodysplasia and Chronic myeloid
    leukemia treated or untreated.
    Patients participating or having participated in the previous month in a clinical
    trial.
    Patients refusing to participate in this study.

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.